Payment overview · 2025
General Payments
$428.58
5 reported records · 2 companies
Healthcare provider profile · identity verified
Benigno Waldo A Dagan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SUMNER, WA · NPI 1235182122
Verified facts
What the public records show
CMS Open Payments records show Benigno Waldo A Dagan, MD received $428.58 in general payments during 2025 across 5 reported records.
ABBVIE INC. accounted for 75.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $322.05 | 75.1% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$106.53 | 24.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $229.33 | 2 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $199.25 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $122.80 | 1 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $106.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 469 | 135 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 439 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 434 | 103 |
| Lisinopril | Lisinopril | 365 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 362 | 91 |
| Omeprazole | Omeprazole | 349 | 82 |
| Oxycodone Hcl | Oxycodone Hcl | 331 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 294 | 81 |
| Losartan Potassium | Losartan Potassium | 274 | 76 |
| Alprazolam | Alprazolam | 266 | 55 |
| Gabapentin | Gabapentin | 259 | 53 |
| Furosemide | Furosemide | 251 | 64 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 250 | 65 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 237 | 36 |
| Metformin Hcl | Metformin Hcl | 235 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 220 | 53 |
| Simvastatin | Simvastatin | 200 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 193 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 176 | 39 |
| Eliquis | Apixaban | 170 | 30 |
| Potassium Chloride | Potassium Chloride | 153 | 39 |
| Trazodone Hcl | Trazodone Hcl | 146 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 138 | 26 |
| Allopurinol | Allopurinol | 135 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 133 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 36 |
| Finasteride | Finasteride | 122 | 27 |
| Lovastatin | Lovastatin | 119 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 24 |
| Xarelto | Rivaroxaban | 107 | 19 |
| Bupropion Xl | Bupropion Hcl | 106 | 24 |
| Ozempic | Semaglutide | 99 | 17 |
| Clonazepam | Clonazepam | 97 | 22 |
| Carvedilol | Carvedilol | 92 | 25 |
| Mounjaro | Tirzepatide | 92 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 26 |
| Metformin Hcl Er | Metformin Hcl | 86 | 22 |
| Montelukast Sodium | Montelukast Sodium | 85 | 18 |
| Meloxicam | Meloxicam | 81 | 22 |
| Glimepiride | Glimepiride | 80 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 18 |
| Lorazepam | Lorazepam | 77 | 19 |
| Pregabalin | Pregabalin | 77 | 17 |
| Aripiprazole | Aripiprazole | 75 | 13 |
| Tramadol Hcl | Tramadol Hcl | 74 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 72 | suppressed |
| Ezetimibe | Ezetimibe | 70 | 15 |
| Sertraline Hcl | Sertraline Hcl | 69 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 68 | 16 |
| Famotidine | Famotidine | 67 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 15 |
| Spironolactone | Spironolactone | 64 | 17 |
| Fenofibrate | Fenofibrate | 61 | 15 |
| Donepezil Hcl | Donepezil Hcl | 59 | 12 |
| Telmisartan | Telmisartan | 59 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 14 |
| Synthroid | Levothyroxine Sodium | 56 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 17 |
| Jardiance | Empagliflozin | 51 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | 12 |
| Temazepam | Temazepam | 47 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 14 |
| Azithromycin | Azithromycin | 44 | 37 |
| Celecoxib | Celecoxib | 44 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 30 |
| Prednisone | Prednisone | 43 | 24 |
| Atenolol | Atenolol | 42 | 11 |
| Valsartan | Valsartan | 42 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 37 | suppressed |
| Estradiol | Estradiol | 37 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | 15 |
| Cilostazol | Cilostazol | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 12 |
| Ibuprofen | Ibuprofen | 32 | 11 |
| Methadone Hcl | Methadone Hcl | 32 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 13 |
| Diazepam | Diazepam | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Nystatin | Nystatin | 26 | 20 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 12 |
| Spiriva Handihaler | Tiotropium Bromide | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 24 | suppressed |
| Febuxostat | Febuxostat | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Bumetanide | Bumetanide | 20 | suppressed |
| Carisoprodol | Carisoprodol | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Olanzapine Odt | Olanzapine | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Vytorin | Ezetimibe/Simvastatin | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $428.58 · 5 records | ABBVIE INC. | CREON, INTERSTIM | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error